scholarly journals Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

10.3791/3627 ◽  
2012 ◽  
Author(s):  
Patrick J. Hanley ◽  
Sharon Lam ◽  
Elizabeth J. Shpall ◽  
Catherine M. Bollard
Keyword(s):  
T Lymphocytes ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Cytotoxic T Lymphocytes ◽  
Umbilical Cord Blood ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

CD4+ Epstein–Barr Virus-Specific Cytotoxic T-Lymphocytes from Human Umbilical Cord Blood

1999 ◽  
Vol 195 (2) ◽  
pp. 81-88 ◽  
Author(s):  
Qi Sun ◽  
Robert L. Burton ◽  
Karen E. Pollok ◽  
David J. Emanuel ◽  
Kenneth G. Lucas
Keyword(s):  
T Lymphocytes ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Cytotoxic T Lymphocytes ◽  
Umbilical Cord Blood ◽  
Epstein Barr Virus ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Determination of Epstein-Barr virus (EBV) incidence in umbilical cord blood (UCB) and assessment of virus DNA via Real-time PCR

2021 ◽  
Vol 29 (1) ◽  
pp. 114-120
Author(s):  
Afsaneh Jahangiryan ◽  
Maryam Kheirandish ◽  
Shahram Samiee ◽  
Zohreh Sharifi ◽  
Mastaneh Alaei
Keyword(s):  
Cord Blood ◽  
Real Time ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

Blood ◽  
2006 ◽  
Vol 108 (8) ◽  
pp. 2874-2880 ◽  
Author(s):  
Claudio G. Brunstein ◽  
Daniel J. Weisdorf ◽  
Todd DeFor ◽  
Juliet N. Barker ◽  
Jakub Tolar ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Antithymocyte Globulin ◽  
Epstein Barr Virus ◽  
Close Monitoring ◽  
Barr Virus ◽  
Increased Risk ◽  
Preparative Regimen ◽  
Epstein Barr

AbstractUmbilical cord blood (UCB) is increasingly used as an alternative source of hematopoietic stem cells for transplantation for patients who lack a suitable sibling donor. Despite concerns about a possible increased risk of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD) after UCB transplantation, early reports documented rates of PTLD comparable to those reported after HLA-matched unrelated marrow myeloablative (MA) transplantations. To further investigate the incidence of EBV PTLD after UCB transplantation and potential risk factors, we evaluated the incidence of EBV-related complications in 335 patients undergoing UCB transplantation with an MA or nonmyeloablative (NMA) preparative regimen. The incidence of EBV-related complications was a 4.5% overall, 3.3% for MA transplantations, and 7% for NMA transplantations. However, the incidence of EBV-related complications was significantly higher in a subset of patients treated with an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (21% vs 2%; P < .01). Nine of 11 patients who developed EBV PTLD were treated with rituximab (anti-CD20 antibody), with the 5 responders being alive and disease free at a median of 26 months. Use of ATG in recipients of an NMA preparative regimen warrants close monitoring for evidence of EBV reactivation and potentially preemptive therapy with rituximab.

Longitudinal dynamics of antigen-specific CD8+cytotoxic T lymphocytes following primary Epstein-Barr virus infection

Blood ◽  
2001 ◽  
Vol 98 (8) ◽  
pp. 2588-2589 ◽  
Author(s):  
Mandvi Bharadwaj ◽  
Scott R. Burrows ◽  
Jacqueline M. Burrows ◽  
Denis J. Moss ◽  
Michelle Catalina ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Virus Infection ◽  
Cytotoxic T Lymphocytes ◽  
Epstein Barr Virus ◽  
Epstein Barr Virus Infection ◽  
Longitudinal Dynamics ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection
Sign in / Sign up

Export Citation Format

Share Document